Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (Nasdaq: SGHT) is an eyecare technology company that regularly issues news about its interventional glaucoma and dry eye businesses. As a manufacturer of ophthalmic medical devices, the company provides updates on its OMNI® and SION® glaucoma technologies and its TearCare® System for evaporative dry eye disease due to meibomian gland disease.
News for SGHT often includes quarterly and annual financial results, revenue guidance updates, and commentary on operating expenses and restructuring plans. The company uses press releases and Form 8-K filings to report results of operations, changes to loan agreements, and targeted cost-reduction initiatives designed to align its operating structure with long-term objectives.
Clinical and scientific developments are another recurring theme. Sight Sciences highlights peer-reviewed publications, systematic reviews, and meta-analyses evaluating the OMNI Surgical System in primary open-angle glaucoma, including standalone and cataract-combination procedures. It also reports on randomized controlled trials and guideline recognition related to the TearCare System in dry eye disease and meibomian gland disease.
Coverage decisions and reimbursement milestones frequently appear in the company’s announcements. Examples include jurisdiction-wide pricing for CPT® code 0563T, which describes the TearCare procedure, established by Medicare Administrative Contractors, and expanded coverage policies from commercial insurers for implant-free, minimally invasive glaucoma surgery procedures that include OMNI.
Corporate governance and leadership changes are also disclosed, such as executive promotions, board resignations, and new officer appointments. Investors following SGHT news can expect a mix of financial updates, clinical evidence summaries, reimbursement developments, and corporate actions related to its interventional eye care technologies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sight Sciences (Nasdaq: SGHT), a company dedicated to transforming eyecare through innovative technology, has announced its participation in the Bank of America Securities 2023 Health Care Conference in Las Vegas on May 10, 2023, at 3:40pm PT. The event will feature a fireside chat accessible via a live and archived webcast on the company’s investors page. Sight Sciences aims to enhance patient care with its products such as the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These minimally invasive solutions target the leading causes of eye issues, improving treatment outcomes over traditional methods.
Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eyecare technology company, will report its financial results for Q1 2023 after market close on May 4, 2023. Management will host a conference call at 1:30 PM PT to discuss these results. Investors can access the live and archived webcast through the company’s website. Sight Sciences develops advanced solutions, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease, targeting prevalent eye diseases through non-invasive methods. These innovations aim to improve patient care and replace outdated treatments, positioning the company strongly in the eyecare market.
Sight Sciences Announces Surgical Glaucoma Investor Symposium
On April 13, 2023, Sight Sciences, Inc. (Nasdaq: SGHT) revealed plans for a Surgical Glaucoma Investor Symposium on May 5, 2023, in San Diego, CA, at 6:00 pm PT. The event will feature insights from leading glaucoma surgeons and remarks from the executive management team.
Attendance is limited and requires advance registration by April 21, 2023. A live webcast will be available on the investor relations website. Sight Sciences specializes in innovative eyecare solutions, focusing on minimally invasive treatments for glaucoma and other prevalent eye diseases.
Notable products include the OMNI® Surgical System for glaucoma management and the TearCare® System for dry eye disease.
Sight Sciences (Nasdaq: SGHT) has announced the appointment of Alison "Ali" Bauerlein as Chief Financial Officer and Treasurer, effective April 3, 2023. Bauerlein brings extensive experience from her previous role at Inogen, where she oversaw financial operations during significant growth phases. CEO Paul Badawi expressed confidence in Bauerlein's ability to support the company's strategic plan and financial infrastructure as it aims for profitable growth. Bauerlein's background in medtech and her previous success in scaling organizations are expected to positively influence Sight Sciences' trajectory in the eyecare technology sector.
Sight Sciences, Inc. (Nasdaq: SGHT) successfully defeated all four patent invalidity challenges from Alcon and Ivantis regarding its Hydrus® Microstent technology. The U.S. Patent Office denied the petitions, confirming the validity of Sight Sciences’ patents. This decision follows a lawsuit filed in 2021, seeking damages and injunctive relief against Ivantis for patent infringement. A jury trial is set for April 8, 2024, in Wilmington, Delaware. Sight Sciences boasts a robust patent portfolio covering innovative approaches to glaucoma treatment and aims to vigorously defend its intellectual property.
Sight Sciences, Inc. (Nasdaq: SGHT) reported strong financial results for Q4 and full-year 2022, with total revenue of $71.3 million, a 46% increase year-over-year. Q4 revenue reached $20.5 million, up 40% compared to Q4 2021. Surgical Glaucoma revenue rose to $18.8 million and Dry Eye revenue surged by 135% to $1.8 million. Operating expenses decreased sequentially to $33.9 million from Q3 2022. However, the net loss for Q4 was $16.9 million, while total operating expenses for 2022 increased by 56% year-over-year to $142.9 million. The company projects 2023 revenue between $89 million and $94 million, indicating expected growth of 25% to 32%.